Atrium Therapeutics Common Stock Technical Analysis
| RNADelisted Stock | USD 14.80 0.13 0.89% |
According to pricing data from the 12th of March 2026, Atrium Therapeutics trades at 14.80 per share. Quantitative signals reflect Mean Deviation of 2.63, standard deviation of 9.91, and Risk Adjusted Performance of -0.08. Volume-adjusted indicators are evaluated relative to historical ranges. Current technical signals are evaluated against industry dispersion.
Atrium Therapeutics Momentum Analysis
Momentum indicators are widely used technical indicators which help to measure the pace at which the price of specific equity, such as Atrium, fluctuates. Many momentum indicators also complement each other and can be helpful when the market is rising or falling as compared to AtriumAtrium |
Atrium Therapeutics 'What if' Analysis
Running a what-if backtest on Atrium Therapeutics Common gives investors a practical way to test how changes in horizon, position size, or market timing might have affected the result. Used properly, this review helps investors decide whether Atrium Therapeutics' historical reward profile was stable enough to support the current thesis.
| 12/12/2025 |
| 03/12/2026 |
Starting with 0.00 in Atrium Therapeutics on December 12, 2025 and exiting today would produce 0.00 in total gains. That corresponds to a 0.0% net return in Atrium Therapeutics overall over 90 days. Atrium Therapeutics has comparable peers such as Jazz Pharmaceuticals, Madrigal Pharmaceuticals, Caris Life, Moderna, Abivax SA, Cytokinetics, and Nuvalent. Peer context helps frame relative positioning. Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies More
Upside and Downside Indicators for Atrium Therapeutics Overview
These indicators describe how Atrium Therapeutics momentum evolves across recent price ranges. They compare current price to recent trend and sentiment readings.
| Information Ratio | -0.12 | |||
| Maximum Drawdown | 80.12 | |||
| Value At Risk | -0.81 | |||
| Potential Upside | 0.3757 |
Market Risk Indicators for Atrium Therapeutics Overview
Risk measures here provide context on Atrium Therapeutics' return distribution and drawdown behavior. The metrics rely on historical prices to describe variability over time.| Risk Adjusted Performance | -0.08 | |||
| Jensen Alpha | -1.19 | |||
| Total Risk Alpha | -0.92 | |||
| Treynor Ratio | -5.23 |
Mean reversion opportunities in Atrium Therapeutics' arise when market prices disconnect from fundamental anchors such as earnings, book value, or historical price-to-earnings multiples.
Atrium Therapeutics Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.08 | |||
| Market Risk Adjusted Performance | -5.22 | |||
| Mean Deviation | 2.63 | |||
| Coefficient Of Variation | -839.07 | |||
| Standard Deviation | 9.91 | |||
| Variance | 98.26 | |||
| Information Ratio | -0.12 | |||
| Jensen Alpha | -1.19 | |||
| Total Risk Alpha | -0.92 | |||
| Treynor Ratio | -5.23 | |||
| Maximum Drawdown | 80.12 | |||
| Value At Risk | -0.81 | |||
| Potential Upside | 0.3757 | |||
| Skewness | -7.89 | |||
| Kurtosis | 63.44 |
Atrium Therapeutics Backtested Returns
Atrium Therapeutics remains characterized by a moderate volatility within the selected investment span. It maintains a Sharpe Ratio (Efficiency) of -0.12, representing negative adjusted performance consistency. We identified twenty-three technical indicators influencing the company's volatility profile. Please review metrics such as mean deviation of 2.63, standard deviation of 9.91, and risk-adjusted performance of -0.08 to assess internal risk calibration. The firm shows a Beta (market volatility) of 0.23, which conveys relatively modest fluctuations relative to the market. As returns on the market increase, Atrium Therapeutics' returns are expected to increase less than the market. However, during a bear market, the loss from holding Atrium Therapeutics is expected to be smaller as well. At this point, Atrium Therapeutics has a negative expected return of -1.29%. Please make sure to double-check Atrium Therapeutics' the relationship between the day median price and relative strength index, to decide if Atrium Therapeutics's performance from the past will be repeated at some future date.
Auto-correlation | -0.66 |
Very good reverse predictability
Atrium Therapeutics Common exhibits very good reverse predictability. Autocorrelation measures the degree of predictability between Atrium Therapeutics time series from 12th of December 2025 to 26th of January 2026 and from 26th of January 2026 to 12th of March 2026. The stronger the relationship between the current interval and its lagged values, the more accurately future price behavior of Atrium Therapeutics may be projected. A serial correlation of -0.66 indicates that around 66.0% of current Atrium Therapeutics price fluctuations can be explained by its historical price movements. Given that Atrium Therapeutics Common has negative autocorrelation for the selected time horizon, market participants may evaluate potential contrarian price behavior over comparable future intervals.
| Correlation Coefficient | -0.66 | |
| Spearman Rank Test | -0.13 | |
| Residual Average | 0.0 | |
| Price Variance | 541.29 |
This technical analysis view for Atrium Therapeutics focuses on price, volume, and trend behavior. Typical tools include moving averages, relative strength index, regressions, and price correlations.
Atrium Therapeutics Technical Analysis
The output start index for this execution was twenty-four with a total number of output elements of thirty-seven. The Average True Range was developed by J. Welles Wilder in 1970s. It is one of components of the Welles Wilder Directional Movement indicators. The ATR is a measure of Atrium Therapeutics volatility. High ATR values indicate high volatility, and low values indicate low volatility.
About Atrium Therapeutics Technical Analysis
Technical analysis of Atrium Therapeutics evaluates price structure, momentum, and volatility clustering. Oscillator extremes can precede mean reversion under certain regimes. Atrium Therapeutics has a market cap of 11.24 B, ROE of -43.98%. 
Gabriel Shpitalnik · Member of Macroaxis Editorial Board
Unless otherwise specified, financial data for Atrium Therapeutics Common is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Updates may occur throughout the day.
Atrium Stock is Curated By:
Gabriel Shpitalnik · Member of Macroaxis Editorial BoardAtrium Therapeutics Technical Indicators
A technical review of Atrium Therapeutics Common can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | -0.08 | |||
| Market Risk Adjusted Performance | -5.22 | |||
| Mean Deviation | 2.63 | |||
| Coefficient Of Variation | -839.07 | |||
| Standard Deviation | 9.91 | |||
| Variance | 98.26 | |||
| Information Ratio | -0.12 | |||
| Jensen Alpha | -1.19 | |||
| Total Risk Alpha | -0.92 | |||
| Treynor Ratio | -5.23 | |||
| Maximum Drawdown | 80.12 | |||
| Value At Risk | -0.81 | |||
| Potential Upside | 0.3757 | |||
| Skewness | -7.89 | |||
| Kurtosis | 63.44 |
Atrium Therapeutics March 12, 2026 Daily Trend Indicators
A technical review of Atrium Therapeutics Common can improve timing discipline by comparing momentum, reversal risk, and confirmation signals across several time horizons. The stronger process confirms one signal with others instead of reacting to one pattern in isolation.
| Accumulation Distribution | 57,842 | ||
| Daily Balance Of Power | 0.10 | ||
| Rate Of Daily Change | 1.01 | ||
| Day Median Price | 15.22 | ||
| Day Typical Price | 15.08 | ||
| Price Action Indicator | -0.35 |
Atrium Therapeutics has a market cap of 11.24 B, operating margin of -295.9%, ROE of -43.98%. See Your Equity Center for portfolio-level analysis. This suggests a position in Atrium Therapeutics Common within the portfolio mix. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. Analysis related to Atrium Therapeutics should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Other Consideration for investing in Atrium Stock
Atrium Therapeutics liquidity profile may be thinner following delisting.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |